Clinical Trial Update: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating olaparib as maintenance monotherapy in relapsed ovarian cancer after a complete or partial response to platinum chemotherapy has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Lynparza) (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy | Phase 3 | Status: COMPLETED